Michael Greenfield, MD
Endocrinology, Diabetes & Metabolism · Mountain View, CANPI 1295873685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.7% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,350 and has fallen 90.8% since, to $217 in 2025.
Across 179 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$501
- Novo Nordisk$436
- Amgen$377
- Radius Health, Inc.$266
- Sanofi-aventis U.S. LLC$248
- AbbVie$229
- plus $2K from 21 others
Across 3 payments — averaging $209,125 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk$627K
What the payments were for
- Food & beverage$3,39892%
- Education$2497%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 20 | $501 |
| Novo Nordisk | 23 | $436 |
| Amgen | 21 | $377 |
| Radius Health, Inc. | 9 | $266 |
| Sanofi-aventis U.S. LLC | 11 | $248 |
| AbbVie | 12 | $229 |
| Lilly USA, LLC | 10 | $211 |
| Insulet Corporation | 12 | $176 |
| Abbott | 9 | $164 |
| Endo Pharmaceuticals Inc. | 6 | $137 |
| Corcept Therapeutics | 6 | $128 |
| Boehringer Ingelheim | 6 | $120 |
| AstraZeneca(2 entities) | 5 | $109 |
| Shire North American Group Inc | 4 | $99 |
| BD | 4 | $93 |
| Merck | 5 | $85 |
| Currax Pharmaceuticals LLC | 3 | $66 |
| Madrigal Pharmaceuticals | 2 | $47 |
| Lifescan, Inc. | 2 | $44 |
| Johnson & Johnson | 2 | $36 |
| Dexcom, Inc. | 1 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Vivus LLC | 1 | $23 |
| Agios Pharmaceuticals, Inc. | 1 | $20 |
| Medtronic | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Senseonics, Incorporated | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tymlos$125
How this compares
$3,706 in reported general payments places this provider in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 118 | $194,584 |
| JardianceEmpagliflozin | 135 | $179,680 |
| MounjaroTirzepatide | 67 | $87,959 |
| RybelsusSemaglutide | 32 | $57,164 |
| FarxigaDapagliflozin Propanediol | 43 | $53,672 |
| JanuviaSitagliptin Phosphate | 31 | $34,574 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $33,647 |
| TradjentaLinagliptin | 29 | $31,383 |
| ProliaDenosumab | 16 | $27,596 |
| GenotropinSomatropin | 26 | $23,931 |
| InvokanaCanagliflozin | 18 | $17,255 |
| LyumjevInsulin Lispro-Aabc | 15 | $15,116 |
| SynthroidLevothyroxine Sodium | 138 | $14,709 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 46 | $5,015 |
| Novolog FlexpenInsulin Aspart | 13 | $5,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $436 | $251,749150 claims |
| Boehringer IngelheimJardiance, Tradjenta | $120 | $211,063164 claims |
| Lilly USA, LLCMounjaro, Lyumjev | $211 | $103,07582 claims |
| AstraZenecaFarxiga | $109 | $53,67243 claims |
| MerckJanuvia | $85 | $34,57431 claims |
| AmgenProlia | $377 | $27,59616 claims |
| Johnson & JohnsonInvokana | $36 | $17,25518 claims |
| AbbVieSynthroid | $229 | $14,709138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Mountain View
- Todd KayeMountain View$298K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.